Charles River Laboratories Total Assets
Charles River Laboratories total assets. Based on the latest financial reports, Charles River Laboratories (CRL) holds total assets worth $7.53 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Charles River Laboratories (CRL) cash flow conversion for how efficiently the company converts equity into cash flow.
Total Assets of Charles River Laboratories (1998–2025)
Total assets of Charles River Laboratories from 1998 to 2025. This chart illustrates how Charles River Laboratories's total assets have evolved over time, based on quarterly financial data. See CRL stock price for real-time trading data and today's change.
Charles River Laboratories - Asset Composition Analysis
Charles River Laboratories Total Assets Breakdown (December 2025)
Charles River Laboratories total assets breakdown as of December 2025. Charles River Laboratories's total assets of $7.53 Billion consist of 20.3% current assets and 79.7% non-current assets. Explore Charles River Laboratories current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $213.77 Million | 3.0% |
| Accounts Receivable | $708.86 Million | 9.9% |
| Inventory | $299.10 Million | 4.2% |
| Property, Plant & Equipment | $2.02 Billion | 28.3% |
| Intangible Assets | $340.00 Million | 4.8% |
| Goodwill | $2.76 Billion | 38.7% |
Asset Composition Trend (1998–2025)
This chart illustrates how Charles River Laboratories's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Charles River Laboratories's current assets represent 20.3% of total assets in 2025, a decrease from 41.5% in 1998.
- Cash Position: Cash and equivalents constituted 3.0% of total assets in 2025, down from 10.6% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 42.0% of total assets, an increase from 14.0% in 1998.
- Asset Diversification: The largest asset category is goodwill at 38.7% of total assets.
Charles River Laboratories Competitors by Total Assets
Key competitors of Charles River Laboratories based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Voxel S.A.
WAR:VOX
|
Poland | zł746.13 Million |
|
Leveljump Healthcare Corp
V:JUMP
|
Canada | CA$18.29 Million |
|
Prodia Widyahusada Tbk PT
JK:PRDA
|
Indonesia | Rp2.57 Trillion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$512.35 Million |
Charles River Laboratories - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.35 | 1.36 | 1.40 |
| Quick Ratio | 1.04 | 1.10 | 1.22 |
| Cash Ratio | 0.00 | 0.17 | 0.22 |
| Working Capital | $394.36 Million | $389.42 Million | $395.29 Million |
Charles River Laboratories - Advanced Valuation Insights
This section examines the relationship between Charles River Laboratories's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.50 |
| Latest Market Cap to Assets Ratio | 1.79 |
| Asset Growth Rate (YoY) | -5.2% |
| Total Assets | $7.14 Billion |
| Market Capitalization | $12.77 Billion USD |
Valuation Analysis
Above Book Valuation: The market values Charles River Laboratories's assets above their book value (1.79x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Charles River Laboratories's assets decreased by 5.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Charles River Laboratories (1998–2025)
The table below shows the annual total assets of Charles River Laboratories from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.14 Billion | -5.22% |
| 2024-12-31 | $7.53 Billion | -8.13% |
| 2023-12-31 | $8.20 Billion | +7.79% |
| 2022-12-31 | $7.60 Billion | +8.24% |
| 2021-12-31 | $7.02 Billion | +27.93% |
| 2020-12-31 | $5.49 Billion | +17.01% |
| 2019-12-31 | $4.69 Billion | +21.70% |
| 2018-12-31 | $3.86 Billion | +31.60% |
| 2017-12-31 | $2.93 Billion | +8.04% |
| 2016-12-31 | $2.71 Billion | +31.10% |
| 2015-12-31 | $2.07 Billion | +9.72% |
| 2014-12-31 | $1.89 Billion | +14.63% |
| 2013-12-31 | $1.64 Billion | +3.67% |
| 2012-12-31 | $1.59 Billion | +1.80% |
| 2011-12-31 | $1.56 Billion | -10.10% |
| 2010-12-31 | $1.73 Billion | -21.36% |
| 2009-12-31 | $2.20 Billion | +2.05% |
| 2008-12-31 | $2.16 Billion | -23.01% |
| 2007-12-31 | $2.81 Billion | +9.70% |
| 2006-12-31 | $2.56 Billion | +0.76% |
| 2005-12-31 | $2.54 Billion | -3.37% |
| 2004-12-31 | $2.63 Billion | +228.54% |
| 2003-12-31 | $799.55 Million | +14.00% |
| 2002-12-31 | $701.34 Million | +22.75% |
| 2001-12-31 | $571.36 Million | +39.15% |
| 2000-12-31 | $410.61 Million | +13.10% |
| 1999-12-31 | $363.06 Million | +54.98% |
| 1998-12-31 | $234.25 Million | -- |
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in … Read more